Nathan H. Fowler, M.D.

Peer-Reviewed Articles

1. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol 182(5):718-723, 2018. e-Pub 2017. PMID: 28771675.
2. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28792260.
3. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol 179(5):851-854, 2017. e-Pub 2016. PMID: 27502933.
4. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma 58(12):1-12, 2017. e-Pub 2017. PMID: 28482717.
5. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2016. PMID: 27378601.
6. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthal Plast Reconstr Surg 33(5):355-360, 2017. e-Pub 2016. PMID: 27636243.
7. Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol 28(9):2094-2106, 2017. e-Pub 2017. PMID: 28430865.
8. Li X, Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, Fowler N, Miranda RN, Zhang M, Ferry JA, Medeiros LJ, Harris NL, Young KH. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. e-Pub 2017. PMID: 28817403.
9. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood 130(4):472-477, 2017. e-Pub 2017. PMID: 28522441.
10. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
11. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. e-Pub 2017. PMID: 28370694.
12. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. e-Pub 2017. PMID: 28379322.
13. Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. e-Pub 2017. PMID: 28382648.
14. Mistry H, Forbes SG, Fowler N. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm . Clin J Oncol Nurs 21(2):53-59, 2017. PMID: 28315558.
15. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2016. PMID: 27983760.
16. Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. Recommendations for Clinical Trial Development in Follicular Lymphoma. J Natl Cancer Inst 109(3), 2017. e-Pub 2016. PMID: 28040699.
17. Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol 35(5):JCO2016708651, 2017. e-Pub 2016. PMID: 28029309.
18. Fowler N. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?. Hematology Am Soc Hematol Educ Program 2016(1):277-283, 2016. PMID: 27913492.
19. Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. e-Pub 2016. PMID: 28031560.
20. Milgrom SA, Cheah CY, Pinnix CC, Smith GL, Dabaja BS, Horace P, Chevez-Barrios P, Fowler NH, Gombos DS. Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. Leuk Lymphoma 57(11):1-7, 2016. e-Pub 2016. PMID: 27075636.
21. Jain P, Prieto VG, Manning JT, Fowler N, Medeiros LJ, Kanagal-Shamanna R. Synchronous Presentation of Intra-nodal Follicular Dendritic Cell Sarcoma and Castleman Disease. Am J Hematol. e-Pub 2016. PMID: 27862216.
22. Awan MJ, Lavertu P, Zender C, Rezaee R, Fowler N, Gibson M, Wasman J, Faulhaber P, Machtay M, Yao M. Posttreatment Positron Emission Tomography/Computed Tomography and p16 Status for Neck Management in Locally Advanced Head and Neck Cancer After Definitive Chemoradiation. Int J Radiat Oncol Biol Phys 96(2S):E386-E387, 2016. PMID: 27674549.
23. Milgrom SA, Cheah C, Pinnix CC, Smith GL, Dabaja B, Horace P, Chevez-Barrios P, Fowler NH, Gombos DS. Acute and Late Toxicity of Bilateral Orbital Irradiation in the Management of Primary Intraocular Lymphoma. Int J Radiat Oncol Biol Phys 96(2S):E490, 2016. PMID: 27674830.
24. Ho JC, Reddy J, Mazloom A, Allen PK, Milgrom SA, Smith GL, Medeiros LJ, Young KH, Fowler NH, Dabaja B, Pinnix CC. Radiation Therapy Improves Outcomes in Patients With Primary Testicular Diffuse Large B-cell Lymphoma. Int J Radiat Oncol Biol Phys 96(2S):S20, 2016. PMID: 27675776.
25. Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. e-Pub 2016. PMID: 27568520.
26. Cheah CY, Mistry HE, Konoplev S, Fowler NH. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma 57(8):1-3, 2016. e-Pub 2016. PMID: 26762971.
27. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. e-Pub 2016. PMID: 27227654.
28. Sehn LH, Chua N, Mayer J, Dueck G, Trnený M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17(8):1081-93, 2016. e-Pub 2016. PMID: 27345636.
29. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 2016. e-Pub 2016. PMID: 27091808.
30. Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood 128(3):331-6, 2016. e-Pub 2016. PMID: 27252232.
31. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. e-Pub 2016. PMID: 27448187.
32. Mahale P, Turturro F, Romaguera JE, Fowler N, Torres HA. The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia. Leuk Lymphoma 57(6):1-13, 2016. e-Pub 2015. PMID: 26402559.
33. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 2016. PMID: 27351173.
34. Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol 27(5):778-87, 2016. e-Pub 2016. PMID: 26802148.
35. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
36. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101(5):531-40, 2016. PMID: 27132279.
37. Kim MM, Dabaja BS, Medeiros J, Kim S, Allen P, Chevez-Barrios P, Gombos DS, Fowler N. Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience. Am J Clin Oncol 39(2):109-13, 2016. e-Pub 2014. PMID: 24390272.
38. Cheah CY, Milgrom S, Chihara D, Gombos DS, Pinnix CC, Dabaja BS, Fowler NH. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol 18(4):575-81, 2016. e-Pub 2015. PMID: 26487691.
39. Akhtari M, Reddy JP, Pinnix CC, Allen PK, Osborne EM, Gunther JR, Milgrom SA, Smith GL, Wogan CF, Fowler N, Rodriguez MA, Dabaja B. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leuk Lymphoma 57(1):1-5, 2016. e-Pub 2015. PMID: 25860237.
40. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
41. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. e-Pub 2015. PMID: 26683805.
42. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 2015. e-Pub 2015. PMID: 26213141.
43. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 2015. e-Pub 2015. PMID: 26250576.
44. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
45. Reddy JP, Akhtari M, Smith GL, Pinnix C, Osborne EM, Gunther JR, Allen PK, Yehia ZA, Fanale M, Rodriguez MA, Fowler N, Milgrom SA, Wogan CF, Dabaja BS. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clin Lymphoma Myeloma Leuk 15(11):664-670.e2, 2015. e-Pub 2015. PMID: 26321471.
46. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med 7(314):314ra185, 2015. PMID: 26582900.
47. Cheah CY, Fowler NH. Chemotherapy-Free Treatment of Follicular Lymphoma: We Have the Ingredients, Now for Some Recipes. Oncology (Williston Park) 29(10):769, 772, 2015. PMID: 26470902.
48. Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 27(5):384-91, 2015. PMID: 26248256.
49. Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol 33(25):2803-11, 2015. e-Pub 2015. PMID: 26195701.
50. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 26(8):1667-77, 2015. e-Pub 2015. PMID: 25712458.
51. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922-6, 2015. e-Pub 2015. PMID: 26193343.
52. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 100(7):e272-4, 2015. e-Pub 2015. PMID: 25820332.
53. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26(6):1175-9, 2015. e-Pub 2015. PMID: 25712454.
54. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. PMID: 25863759.
55. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 2015. PMID: 25863764.
56. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125(21):3357-9, 2015. PMID: 25999447.
57. Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Ann Hematol 94(4):633-641, 2015. e-Pub 2015. PMID: 25630297.
58. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2014. PMID: 25445468.
59. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol 10(1):206, 2015. e-Pub 2015. PMID: 26407853.
60. Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw 13(1):41-50, 2015. PMID: 25583768.
61. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
62. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 2014. e-Pub 2014. PMID: 25039868.
63. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol 167(2):207-13, 2014. e-Pub 2014. PMID: 25040450.
64. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
65. Fowler NH. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma. Clin Adv Hematol Oncol 12(9):608-10, 2014. PMID: 25654483.
66. Liao B, Kamiya-Matsuoka C, Gong Y, Chen M, Wolf BA, Fowler NH. Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease. J Neurol Sci 343(1-2):46-50, 2014. e-Pub 2014. PMID: 24880537.
67. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical Value of Magnetic Resonance Imaging and Other Baseline Testing for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma. Leuk Lymphoma 55(5):1013-7, 2014. e-Pub 2013. PMID: 23879202.
68. Fowler N. Indolent and mantle cell NHL: the future is BRIGHT. Blood 123(19):2905-6, 2014. PMID: 24810622.
69. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
70. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. e-Pub 2013. PMID: 24332512.
71. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
72. Kahl BS, Fowler NH, Czuczman MS. Integrating emerging treatment options in mantle cell lymphoma. Clin Adv Hematol Oncol 11(12 Suppl 19):1-15, 2013. PMID: 24893155.
73. Fowler N.. Frontline Management Strategies for Younger, Fit Patients with Mantle Cell Lymphoma. Clinical Advances in Hematology/Oncology 11(12):4-6, 2013.
74. Rosen ST, Link BK, Fowler NH. Unmet needs in the treatment of mantle cell lymphoma. Clin Adv Hematol Oncol 11(11 Suppl 18):1-19, 2013. PMID: 24893041.
75. Fowler N.. Novel Treatment Approaches to Mantle Cell Lymphoma. Clinical Advances in Hematology/Oncology 11(11):14-18, 2013.
76. Oki Y, Buglio D, Fanale MA, Fayad L, Copeland AR, Romaguera J, Kwak LW, Pro B, Faria SD, Neelapu SS, Fowler N, Hagemeister FB, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. e-Pub 2013. PMID: 24097867.
77. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 2013. e-Pub 2013. PMID: 23590726.
78. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. J Immunol 190(12):6681-93, 2013. e-Pub 2013. PMID: 23686488.
79. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell Non-Hodgkin lymphoma. Br J Haematol. e-Pub 2013. PMID: 23795711.
80. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 2013. e-Pub 2012. PMID: 23276888.
81. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah JJ, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia, 2013. e-Pub 2013. PMID: 23545991.
82. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. J Clin Oncol 31(1):88-94, 2013. e-Pub 2012. PMID: 23045577.
83. Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013:553-60, 2013. PMID: 24319231.
84. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol Educ Book:366-72, 2013. PMID: 23714549.
85. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
86. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. e-Pub 2011. PMID: 22015451.
87. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
88. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 29(25):3389-95, 2011. e-Pub 2011. PMID: 21810687.
89. Fowler N. Role of Maintenance Rituximab (Rituxan) Therapy in the Treatment of Follicular Lymphoma. Pharmacy and Therapeutics 36(9):590-598, 2011.
90. Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma. Clin Nucl Med 36(4):317-9, 2011. PMID: 21368613.
91. Mazloom A, Rodriguez A, Ha CS, Medeiros LJ, Wogan C, Shihadeh F, Allen P, Fowler N, Dabaja B. Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma. Cancer. e-Pub 2010. PMID: 21157949.
92. Phan J, Mazloom A, Medeiros J, Shihadeh F, Rodriguez A, Fayad L, Fowler N, Reed V, Horace P and Dabaja B. The benefit of consolidative radiation therapy in patients with diffuse large b-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology 28(27)(4):4105-7, 2010. PMID: 20713859.
93. Mazloom A, Fowler N, McLaughlin P, Iyengar P, Cabinillas F, Fayad L, Pro B, Medeiros J, Rodriguez A, Reed V, Urbauer D, Gonzalez G, Dabaja B. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma 51(7):1217-1224, 2010. PMID: 20443676.
94. Goldman L, Ezzat S, Mokhtar N, Abdel-Hamid A, Fowler N, Gouda I, Eissa S, Abdel-Hamid M, Loffredo C. Viral and non-viral risk factors for non-Hodgkin's Lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control 20(6):981-7, 2009. e-Pub 2009. PMID: 19263231.
95. Fowler N, Younes A. There will be blood: targeting tumor vasculature. Blood 113(10):2121-2122, 2009. PMID: 19264922.
96. Fowler N, Asatiani E, Cheson B. Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. Leuk Lymphoma 49(1):156-8, 2008. PMID: 18203026.
97. Fowler N, Spell D. Case report. Parotid gland metastasis as the initial manifestation of a non-small cell lung cancer. Southern Medical J. Vol 95:S:25, 2002.

Abstracts

1. Fowler N, Neelapu S, Samaniego F, Forbes S, Hagemeister FB, Fayad L, Feng L, Turturro F, Westin JR, Arafat J, Neal E, Nastoupil LJ. Activity of the Immunologic Doublet of Lenalidomide Plus Obinutuzumab in Relapsed Follicular Lymphoma: Results of a Phase I/II Study. J Clin Oncol 35(15), 2017.
2. Nastoupil LJ, Westin JR, Fowler N, Fanale MA, Samaniego F, Oki Y, Obi C, Cao J, Cheng X, Ma MCJ, Wang Z, Chu F, Feng L, Zhou S, Davis RE, Neelapu S. Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Interim Results of an On Open-Label, Phase II Study. J Clin Oncol 35(15), 2017.
3. Nastoupil LJ, Lunning MA, Vose J, Schreeder MT, Siddiqi T, Flowers C, Cohen JB, Burger JA, Wierda WG, O'Brien SM, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and Activity of Chemo-free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients with Advanced CLL and NHL. J Clin Oncol 35(15), 2017.
4. Witzig TE, Casulo C, Cartron G, Ruan J, Rule S, Ando K, Burton C, Pinto A, Gouill SL, Fowler NH, Zinzani PL, De Bedout S, Kilavuz N, Rettby N, Czuczman MS, Santoro A. Phase I/II Study of Durvalumab (anti–PD-L1 antibody) as Monotherapy and in Combination in Patients with Lymphoma or Chronic Lymphocytic Leukemia. J Clin Oncol 35(15), 2017.
5. Fowler NH, Flinn I, Rule S, Chen RW, Kwei L, Beaupre DM, Chu AD, Gordon LI. A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab Versus Placebo in Combination with Rituximab in Patients with Treatment-naive Follicular Lymphoma (PERSPECTIVE). J Clin Oncol 35(15), 2017.
6. Shi Q , Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol 35(5):552-560, 2017.
7. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai Cm, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging Activity for R-CHOP in Advanced Stage Nodular Lymphocyte–predominant Hodgkin Lymphoma. Blood 130(4):472-477, 2017.
8. Hu B, Loghavi S, Fayad L, Noorani M, Fowler N, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu S, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of De Novo CD5+ Diffuse Large B-Cell Lymphoma (DLBCL) in The Rituximab (R) Era. J Clin Oncol 35(15), 2017.
9. Issa A, Sathyanarayanan V, Fanale MA , Oki Y , Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH , Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell T, Pinnix CC, Fayad L, Westin JR. Outcomes of Diffuse Large B-cell Lymphoma with MYC and/or BCL2 Protein Expression Treated with Intensive Chemotherapy. J Clin Oncol 34(15), 2016.
10. Burris HA, Flinn I, Lunning MA, Vose J Fowler NH, Nastoupil LJ, O'Brien SM, Schreeder MT, Patel MR, Fenske T, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin HP, Weiss MS, O'Connor OA. Long-term Follow-up of the PI3Kδ Inhibitor TGR-1202 to Demonstrate a Differentiated Safety Profile and High Response Rates in CLL and NHL: Integrated-analysis of TGR-1202 Monotherapy and Combined with Ublituximab. J Clin Oncol 34(15), 2016.
11. Fowler NH, Pearlberg J, Brail LH, Shi W, Jiang L, Condon C, Rummel MJ. FRESCO: A phase 2, Randomized Study of Duvelisib Plus Rituximab vs R-CHOP in Patients with Relapsed/refractory Follicular Lymphoma Who Have Progressed Within 24 Months of Receiving an Alkylator-based Chemotherapy Regimen. J Clin Oncol 34(15), 2016.
12. Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez A, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. Blood 128(22):106, 2016.
13. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Medeiros LJ, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood 128(22):4153, 2016.
14. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu S, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Blood 128(22):1833, 2016.
15. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil L, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood 128(22):4208, 2016.
16. Jain P, Kanagal-Shamanna R, Lucas FS, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JR, Medeiros J, Fowler N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and Acalabrutinib). Blood 128(22):2975, 2016.
17. Gopal AK, Schuster SJ, Fowler N, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Jurczak W, Morton J, Osmanov D, Gartenberg GJ, Vermeulen J, Balasubramanian S, Wang SS, Deshpande S, Salles GA. Ibrutinib as Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study. Blood 128(22):1217, 2016.
18. Fowler N, Nastoupil L, Vos SD, Knapp M, Flinn IW, Chen RW, Advani RH, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre DM, Neuenburg JK, Palomba ML. Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. Blood 128(22):180, 2016.
19. Cheah CY, Fowler NH. Idelalisib in the Management of Lymphoma. Blood 128(3):331-336, 2016.
20. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE and Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood 126(23):3984, 2015.
21. d Vos S, Swinnen L, Kozloff M, Wang, D, Reid E, Nastoupil L. Fowler N, Cordero J, D'Amico D, Dielh S, Dunbar M, Zhu M, Wong S, Enschede SH, Clien D, Humerickhouse RA and Flowers C. A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in patient swith Relapsed or Refractory Non-Hodgkin's Lymphoma. Blood 126(23):255, 2015.
22. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE and Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood 126(23):2738, 2015.
23. Chihara D, Oki Y, Westin JR, Nastoupil L, Fayad LE, Samaniego F, Wesson E, Ruben C, Horowitz SB, Feng L, Garg N, Ahmed S, Khouri IF, Hosing CM, Romaguera JE, Fowler N and Fanale MA. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Blood 126(23):3987, 2015.
24. Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre DM, Neuenburg JK and Palomba ML. Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. Blood 23(470), 2015.
25. Fanale, MA, Wang Z, Ma W, Oki Y, Hagemeister, F, Fayad, LE, Fowler, N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto T, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood 126(23):2705, 2015.
26. Fowler N, Boyd TE, Sharman JP, Smith SM, Clow F, Chu AD and Advani RH. Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. Blood 126(23):2706, 2015.
27. Fowler N, Pinto RM, Cheah CY, Neelapu S, Turturro F, Hagemeister FB, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F and Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood 126(23):2742, 2015.
28. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu JS, Hagemeister FB, Fanale MA, Oki Y, Shah J, Thomoas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ and Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood 126(23):3969, 2015.
29. Wang B, Zhang L, Pham L, Tao W, Zhang H, Xie J, Chen W, Cai Q, Zou D, Zhao D, Sun X, Liang R, Wang J, Nomie K, Fowler N and Wang M. The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma. Blood 126(23):5126, 2015.
30. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE and Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 126(23):1502, 2015.
31. Lunning MA, Vose J, Fowler N, Nastoupil L, Burger JA, Wierda W, Schreeder MT, Siddiqi T, Flowers C, Cohen JB, Blumel S, Miguel M, Cutter K, Pauli EK, Handy R, Sportelli P, HP M, Weiss MS and O'Brien S. Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. Blood 126(23):1538, 2015.
32. Jain P, Patel KP, Futreal A, Gumbs C, Hu S, Ramos CB, Wang M, Romaguera J, Fayad LE, Orlowski R, Medeiros J and Fowler N. Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS). Blood 23(2700), 2015.
33. Cheah CY, Chihara D, Sevin A, Horowitz S, Oki Y, Fowler N, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Westin J, Romaguera J, Fayad L, Samaniego F and Fanale MA. Patients with Classical Hodgkin Lymphoma Failing Brentuximab Vedotin have Brief Responses to Salvage Therapies and Limited Survival. HAA Annual Scientific Meeting 2015, 2015.
34. Fowler N, Cheah C, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Kwak L, Romaguera J, Fanale M, Fayad L, Claret L, Feng L, Davis ER and Samaniego F. Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL. 13th International Conference on Malignant Lymphoma (Palazzo di Congressi, Lugano, Switzerland), 2015.
35. Fowler N, Nastoupil L, Lunning MA, Vose J, Siddiqi T, Flowers C, Cohen JB, Schreeder MT, Miguel M, Blumel S, Phye B, Tse W, Pauli E, Cutter K, Sportelli P, Miskin H, Weiss M, Vakkalanka S, Viswanadha S and O'Brien SM. Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies. J Clin Oncol(33):(supp; abstr 8501), 2015.
36. Leonard J, Gribben J, Trněný M, Scheinberg P, Tobinai K, Fowler N, Kilavuz N, Fustier P and Amoroso B. AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab.J Clin Oncol. J Clin Oncol 33(suppl;abstr TPS8603), 2015.
37. Lunning MA, Vose J, Fowler NH, Nastoupil L, Schreeder M, Siddiqi T, Flowers C, Cohen JB, Blumel S, Miguel M, Tse W, Pauli E, Cutter K, Sportelli P, Miskin H, Weiss M, Vakkalanka S, Viswanadha S and O'Brien SM. Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL. J Clin Oncol 33(suppl; abstr 8548), 2015.
38. Chihara D, Pro B, Loghavi S, Miranda R, Medeiros LJ, Fanale M, Hagemeister FB, Fayad L, Romaguera J, Samaniego F, Neelapu S, Younes A, Fowler N, Rodriguez MA, Wang M, Kwak L, McLaughlin P and Dang N, Oki Y. Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). J Clin Oncol J Clin Oncol(suppl; abstr 8538), 2015.
39. De Vos D, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Cordero J, Gifford M, D'Amico D, Dunbar M, Zhu M, Salem A, Enschede S, Ricker J, Chien D, Humerickhouse R and KozloffInterim M. results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL). J Clin Oncol 33:(suppl; abstr 8535), 2015.
40. Sargent D, Shi Q, De Bedout S, Flowers C, Fowler N, Fu T, Hagenbeek A, Herold M, Hoster E, Huang J, Kimby E, Ladetto M, Morschhauser F, Nielsen T, Takeshita K, Valente N, Vitolo U, Zucca E and Salles G. Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts). J Clon Oncol 33(suppl; abstr 8504), 2015.
41. Sehn LH, Chua NS, Mayer J, Dueck GS, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Leonard A, Lugtenburg P, Franklin N, Fritsch EW, Fingerle-Rowson G and Cheson B. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol 33(suppl; abstr LBA8502), 2015.
42. Fanale M, Hagemeister FB, Fayad L, Oki Y, Fowler N, Romaguera J, Shah N, Chuang H, Feng L, Horowitz SB, Wesson E, Hutto TY, Muzzafar T, Samaniego F and Davis RE. 56th ASH Annual Meeting. A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas, 2014.
43. Fowler NH. R2-CHOP vs R-CHOP for Diffuse Large B-Cell Lymphoma. Clin Adv Hematol Oncol 12(9):608-10, 2014. PMID: 25654483.
44. de Vos S, Flowers CR, Wang D, Swinnen LJ, Fowler N, Reid E, Gifford M, D'Amico D, Dunbar M, Zhu M, Yang J, Enschede SH, Ricker JL, Chien D, Humerickhouse RA and Kozloff M. The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma. Blood 124:1722, 2014.
45. de Vos S, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler N, Sharman JP, Boccia RV, Barrientos JC, Rai K, Boyd TE, Furman RR, Holes LM, Kim Y, Godfrey WR and Leonard JP. Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results. Blood 124:3063, 2014.
46. Mahale P, Turturro F, Romaguera J, Fowler N and Torres HA. The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia. Blood 124:4448, 2014.
47. Furman RR, de Vos S, Barrientos JC, Schreeder MT, Flinn IW, Sharman JP, Boyd TE, Fowler N, Leonard JP, Rai KR, Kim Y, Viggiano A, Jahn TM and Coutre SE. Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood 124:5653, 2014.
48. Lee SE, Percivalle E, Cheng X, Lizee G, Fowler N, Davis RE and Neelapu S. Intratumoral and Peripheral Blood T Cells Recognize Mutated Neo-Antigens in Follicular Lymphoma. Blood 124:809, 2014.
49. Ahmed MA, Fowler N, Ma L, Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin JR, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren EM, Davis RE and Neelapu S. SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy. Blood 124:1629, 2014.
50. Gopisetty A, Foglietta M, Zhang M, Wang Z, Fowler N, Davis RE and Neelapu S.. Prosurvival and Chemoprotective Effects of Tumor-Associated Macrophages Reversed By Anti-CSF-1R Monoclonal Antibody in B-Cell Lymphomas. Blood 124:498, 2014.
51. Mahale P, Romaguera J, Turturro F, Fowler N and Torres HA. Development of Non-Hodgkin’s Lymphoma As Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy – a Case Series. Blood 124:5414, 2014.
52. Lunning MA, Vose JM, Schreeder MT, Fowler N, Nastoupil L, Siddiqi T, Blumel S, Pauli EK, Cutter K, Tse W, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Viswanadha S and O'Brien S. Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. Blood 124:801, 2014.
53. Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez MA, Samaniego F, Fowler N, Oki Y, Turturro F, Westin JR, Kwak L, Dabaja B, Feng L, Davis RE and Neelapu S. Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma. Blood 124:1735, 2014.
54. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak L, Neelapu S, Wang M, Feng L and Younes A. Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma. Blood 124:3093, 2014.
55. Phansalka K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera J, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, Davis RE and Neelapu S. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood 124:3048, 2014.
56. Fowler N, Hiddemann W, Leonard J, Rose E, Ahmadi T, Vermeulen J, Larsen J, Sun S, Mentzer L, Wang SS, Yeh TM and Salles G. A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma. ASCO, 2014.
57. Jain P, Patel K, Bueso-Ramos C, Romaguera J, Fayad L, Kwak L and Fowler N. Treatment of dendritic cell sarcoma: 18-year experience at the MD Anderson Cancer Center. J Clin Oncol 32(suppl;abstr 8596):5s, 2014.
58. Nastoupil L, Neelapu S, Samaniego F, Hagemeister FB, Romaguera J, Kwak L, Wang M, Fayad L, Fanale M, Oki Y, Westin J, Rodriguez MA, Cabanillas F, McLaughlin P and Fowler N. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32(suppl; abstr 8528):5s, 2014.
59. Hong DS, Younes A, Fayad LE, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M, Hughes SG, Kwoh TJ, MacLeod R, Norris D, Baldwin R, Hung G, Monia B, Kurzrock R. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol ASCO Annual Meeting(8523), 2013.
60. Barrientos JC, Furman RR, Leonard J, Flinn I, Roop Rai K, De Vos S, Schreeder MT, Wagner-Johnston ND, Porter Sharman J, Boyd TE, Fowler NH, Holes L, Johnson DM, Li D, Dansey RD, Jahn TM, Coutre SE. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol ASCO Annual Meeting(7017), 2013.
61. Leonard J, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Holes L, Johnson DM, Kim Y, Dansey RD, Godfrey WR, De Vos S. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. J Clin Oncol ASCO Annual Meeting(8500), 2013.
62. Wagner-Johnston N, De Vos S, Leonard J, Porter Sharman J, Schreeder MT, Boccia RV, Barrientos JC, Coutre SE, Flinn I, Boyd TE, Holes L, Johnson DM, Kim Y, Dansey RD, Godfrey WR, Fowler NH. Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol ASCO Annual Meeting(8501), 2013.
63. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol:366-72, 2013. PMID: 23714549.
64. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. J Immunol, 2013. PMID: 23686488.
65. Fowler N, de Vos S, Schreeder M, Leonard J, Flinn I, Coutre S, Wagner-Johnston N, Sharman J, Boccia R, Barrientos J, Boyd T, Holes L, Lannutti B, Johnson D, Jahn T, Miller L, and Godfrey W. Combinations of the phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor Gs-1101 (Cal-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent non-Hodgkin lymphoma: Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
66. Coutre S, Leonard J, Furman R, Barrientos J, de Vos S, Flinn I, Schreeder M, Wagner-Johnston N, Sharman J, boyd T, Fowler N, Holes L, Lannutti B, Johson D, Miller L, and Jahn T. Combinations of the slective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (Cal-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
67. Fanale M, Lai C, Rimes S, Ramirez M, Hagemeister F, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J, and Milbourne A. Positive maternal-fetal outcomes with treatment of lymphoma during pregnancy: UT MD Anderson Cancer Center prospective experience. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
68. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M, Younes A, Rodrigues MA, Orlowski R, Wang M, Ouzounian S, Samaniego F, and Fayad L. R-HCVAD alternating with R-methotrexate cytrabine in younger patients (pts) with IH and high-risk age adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
69. Rawal S, Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladadayuthapani V, Sharma R, Delgado D, Wallace M, Heise C, Lacerte L, Samaniego F, Davis E, and Neelapu S. Activation of T and NK cells following lenalidomide therapy in patients with follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
70. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu S. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
71. Oki Y, Chuang H, Chasen B, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister FB, Rodriguez A, Neelapu S, Samaniego F, Kwak L, and Younes A. The prognostic value of interim PET scan in patients with classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
72. Fowler N, Neelapu S, Hagemeister F, McLaughlin P, Kwak L, Roamguera J, Fnaale M, Fayad L, Orlowski R, Wang M, Turturro F, Oki Y, Lacerte L, and Samaniego F. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase II study. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
73. Nelson K, Samaniego F, Hagemeister F, Lacerte L, Kwak L Neelapu S, Fayad L, LeBlanc D, and Fowler N. Dermatologic side effects of lenalidomide and rituximab in indolent lymphoma. 2012 Pan Pacific Lymphoma Conference, 2012.
74. Gardner K, Dabaja B, Reed V, Kim M, Gambos D, Sorenson E, and Fowler N. Primary intraocular diffuse large B-cell lymphoma: Outcomes following combined modality treatment. 2012 Pan Pacific Lymphoma Conference, 2012.
75. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA), 2012.
76. Fowler N, Munteanu M, Davis G, Brown P, Czuczman M. Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
77. de Vos S, Schreeder M, Flinn I, Coutre S, Leonard J, Wagner-Johnston N, Fowler N, Boccia R, Barrientos J, Boyd T, Sharman J, Holes L, Lannutti B, Johnson D, Jahn T, and Miller L. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor, Cal-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin's lymphoma (iNHL). Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
78. Sharman J, de Vos S, Leonard J, Furman R, Coutre S, Flinn I, Schreeda M, Barrientos J, Wagnor-Johnston N, Boyd T, Fowler N, Holes L, Lannutti B, Johnson D, Jahn T, and Langdon M. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
79. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez M, Neelapu S, Samaniego F, Younes A, and Kwak L. Effects of aprepitant on drug metabolism in lymphoma patients receiving multi-day chemotherapy regimen of cyclophosphamide, doxorubicon, vincristine, prednisone, + rituxan (R/CHOP): Randomized, cross-over study. Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
80. Fowler N, Kahanic S, Ferero A, Murteanu M, Davis G, Brown P, Van Den Neste E, Offner F, Bron D, and Czuczman M. Results of a phase II study with bendamustine and ofatumumab in untreated indolents B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
81. Khouri I, Saliba R, Valverde R, Samuels B, Korblin M, Alousi A, Anderlini P, Bashir Q, de Lima M, Hosing C, Kebriaei P, Nieto Y, Popat U, Qazilbash M, Neelapu S, Fowler N, Samaniego F, Wang L, Champlin R, and Macainlac H. Nonmyeloablative allogenic stem cell transplantation with/without 90yttrium ibritumomab tiexetan (90YIT) is curative for relapsed follicular lymphoma: Median 9 year follow-up results. Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
82. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, and McLaughlin P. Phase II study with R-FND followed by 90-Y Ibritumomab tiuxetan radioimmuntherapy and rituximab maintenance for untreated high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
83. Fowler N, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu S, Fayad L, Orlowski R, Wang W, Pro B, Lacerte L, Samaniego f. High Response Rates with Lenalidomide Plus Rituximab for Untreated Indolent B cell non-Hodgkins Lymphom. Ann Oncol 22(Suppl 4), 2011.
84. Fowler N, Mclaughlin P, Fisch M, Dakhil S, Bury M, Fayad L, Shah J, Neelapu S, Romaguera J, Rodriguez D, Ayala A, Kwak L. Rituximab plus sargramostim for the treatment of newly diagnosed follicular lymphoma: Final Results of a Phase II study. Ann Oncol 22(Suppl 4), 2011.
85. R. Advani, J. P. Sharman, S. M. Smith, D. A. Pollyea, T. E. Boyd, B. W. Grant, K. S. Kolibaba, J. J. Buggy, A. Hamdy, N. H. Fowler. Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase 1 study. Journal of Clinical Oncology 29(15), 2011.
86. Burger J, O'Brien S, Fowler N, Advani R, Sharman J, Furman R, Izumi R, Buggy J, Loury D, Hamdy A, Byrd J, and Blum K. Thr Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demostrates promising clinical activity in chronic lymphomcytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An update on ongoing phase I studies. Blood (ASH Annual Meeting Abstracts) 116(21), 2010.
87. Fowler N, Sharman J, Smith S, Boyd T, Grant B, Kolibaba K, Furman R, Buggy J, Loury D, Hamdy A, and Advani R. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 116(21), 2010.
88. Padmanabhan S, Shea T, Vose J, Reeder C, Berdeja J, McDonagh K, Goy A, Kelly K, Zhou X, Liu H, Fingert H, and Fowler N. Phase I study of an investigational aurora A kinase inhibitor MLN8237 in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 116(21), 2010.
89. Batty N, Ghonimi E, Feng L, Younes A, Rodriguez A, Wager E, Martinez F, Wang M, McLaughlin P, Fowler N, and Hagemeister F. Blood transfusion and erythropoiesis stimulating agents (ESAs) use in patients with diffuse large B-cell lymphoma (DLBCL). Blood (ASH Annual Meeting Abstracts) 116(21), 2010.
90. Okoroji G, Silva L, Saliba R, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, and Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): Allografting vs conventional therapy. Blood (ASH Annual Meeting Abstracts) 116(21), 2010.
91. Fowler N, Sharman JS, Smith SS, Pollyea DP, Boyd TB, Grant BG, Kolibaba KK, Buggy JB, Hamdy AH, Advani, RA. A Phase I Trial of Btk inhibitor PCI-32765 in patients with relapsed non-Hodgkin's lymphoma: Evidence of antitumor activity. Haematologica 95(371(Suppl 2)), 2010.
92. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale M, Neelapu SS, Fayad LE, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Meeting Abstracts 28(15s (Suppl)), 2010.
93. Advani R, Sharman JP, Smith SM, Pollyea DA, Boyd TE, Grant BW, Kolibaba KS, Buggy JJ, Hamdy A, Fowler NH. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. ASCO Meeting Abstracts 28(15s (Suppl)), 2010.
94. Perini GF, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler NH, Hagemeister F, Samaniego F, Kwak LW, Fayad L. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement, clinica presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M.D. Anderson Cancer Center. ASCO Meeting Abstracts 28(15s (Suppl)), 2010.
95. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Buesno-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, and Romaugera J. Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome. Blood (ASH Annual Meeting Abstracts) 114(22):48, 2009.
96. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, and Samaniego F. A biologic combination of lenalidomide and rituximab for front-Line therapy of indolent b-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 114(22):683, 2009.
97. Westin J, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, and Hagemeister F. Bone loss in lymphoma patients receiving frontline therapy: Urine NTx and bone specific alkaline phosphatase provide early evidence of zoledronic acid response. Blood (ASH Annual Meeting Abstracts) 114(22):1508, 2009.
98. Khouri I, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji G, Bassett R, Amin A, Anderlini P, De Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak A, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, and Podoloff D. Stem cell transplantation with 90yttrium ibritumomab tiuxetan (90YIT) in non-Hodgkin's lymphoma (NHL): Observations from PET pre-treatment imaging and responses in allografted refractory follicular histologies. Blood (ASH Annual Meeting Abstracts) 114(22):357, 2009.
99. Fowler N, Kahl B, Rosen P, Matous J, Cashen A, Jacobs S, Letzer J, Amin B, Williams M, Ross M, Smith S, Saleh A, Shi H, Parasuraman S, and Cheson B. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: Encouraging activity in the phase 2 VERTICAL study. Blood (ASH Annual Meeting Abstracts) 114(22):384, 2009.
100. Mazloom A, Fowler N, Iyengar P, and Dabaja B. Primary testicular diffuse large b-cell lymphoma, M.D. Anderson Cancer Center experience. Blood (ASH Annual Meeting Abstracts) 114(22):1055, 2009.
101. Pollyea D, Smith S, Fowler N, Boyd T, Smith A, Sirisawad M, Honigberg L, Hamdy A, and Advani R. A phase I dose escalation study of the Btk inhibitor PCI-32765 in relapsed and refractory b cell non-Hodgkin lymphoma and use of a novel flourescent probe pharmacodynamic assay. Blood (ASH Annual Meeting Abstracts) 114(22):1430, 2009.
102. Fowler N, Khan S, and Gilliam M. Non-Hodgkin's lymphoma and hepatitis c: prevalence of co-infection and outcomes following anti-viral therapy: a review of the literature. 2009 Pan Pacific Lymphoma Conference, 2009.
103. Fowler N, McLaughlin P, Kwak L, Fanale M, Hagemeister F, Fayad L, Pro B, and Samaniego F. Lenolidomide and rituxan for untreated indolent b cell non-Hodgkin's lymphoma. ASCO Meeting Abstracts 27(15s), 2009.
104. McLaughlin P, Neelapu S, Fanale M, Rodriguez M, Ayala A, Pro B, Hagemeister F, Younes A, Neel S, Fowler N, Hess M, and Kwak L. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 112:3056, 2008.
105. Cataldo V, Thompson M, Toth B, Sanjoro P, Bekele N, Jimenez C, Murphy W, Huen A, Arbuckle R, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, and Hagemeister F. Bone loss in patients with previously untreated lymphoma: The effect of periodontal disease on the use of zoledronic acid. Blood (ASH Annual Meeting Abstracts) 112:5297, 2008.
106. S.A. Siddique, N. Fowler, E. Asatiani, B. Mavromatis, P. Cohen, C.M. Kessler and B.D. Cheson. Infectious complications associated with alemtuzumab treatment. ASCO Meeting Abstracts 25(18S), 2007.
107. DeVos S, Wilson W, Gerecitano J, Goy A, Kenkre V, Barr P, Blum K, Shustov A, Advani R, Fowler N, Vose J, Lih C, Williams M, Schmitz R, Yang Y, Pittaluga S, Wright, G, Kunkel L, McGreivy J, Beaurpe D, Balasubramanian S, Cheng M, Moussa D, Chang L, Buggy J, Staudt L. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B-cell-like (ABC) subtype of relapsed/refractory (R/R) DLBCL: Interim. Haematologica.
108. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister F, Allen R, Feng L, Baladandayuthapani V, Yehudar R, Davis E, Neelapu S. Phase II safety and efficacy study of pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. Annals of Oncology.
109. Coutre S, Leonard J, Furman R, Flinn I, de Vos S, Rai K, Schreeder M, Wagner-Johnston, Sharman J, Boyd T, Fowler N, Kim Y, Holes L, Johnson D, Dansey R, Jahn T, Barrientos J. Update on a phase I study of the selective P13K-delta inhibitor, idelaslisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic leukemia. Haematologica.

Book Chapters

1. Nastoupil L, Cheah CY, Medeiros LJ, Fowler N. Indolent Lymphomas. In: The MD Anderson Manual of Medical Oncology. Third. Cenveo: New York, USA, 133-151, 2016.
2. Fowler N, McLaughlin P. Non-Hodgkin's Lymphoma. In: Advances in Malignant Hematology. Wiley-Blackwell: Oxford, UK, 2011.
3. Fowler N, Horowitz S, McLaughlin P. Therapy of B-cell lymphoproliferative disorders. In: Experimental and Clinical Hematopathology. Springer/Humana, 2010.
4. McLaughlin P, Fowler N, Liu N, Medeiros J. The Indolent Lymphomas. In: The MD Anderson Manual of Medical Oncology, 2nd Edition. McGraw-Hill, 2010.